Case Study

Sandoz (B): The art of staying true to your mission

10 pages
September 2025
Reference: IMD-2670

This case series explores Sandoz’s spin off from Novartis, which was finalized on 4 October 2023. Case B looks at Sandoz once it has become independent. The hard work of figuring out the best way to spin off is done, a new strategy created, and some difficult choices made. But now how will CEO Richard Saynor and his leadership team ensure that Sandoz is fit for purpose?

Learning Objective
  • Understand the impact of the founding decisions.
  • Explore whether the spin-off choice was correct.
  • Be able to evaluate whether the chosen strategy decisions fit with the new organization.
Keywords
Strategy, Leadership, Global Business, Generic Drug, Spin-off, Healthcare, Life Science, Board Conflict, Chief Executive Officer, Good Health, Well-being, Reduced Inequalities
Settings
World/global, Switzerland
Healthcare, Pharmaceuticals
2022-2024
Type
Field Research
Copyright
© 2025
Available Languages
English
Related material
Teaching note
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics